Regeneron's Potential Obesity Treatment Could Preserve Muscle Mass

Dow Jones

Sep 17

By Connor Hart

Regeneron Pharmaceuticals said a mid-stage study of its potential obesity treatment found that it could meaningfully preserve muscle mass while enhancing fat loss.

The biotechnology company said Wednesday the combination of semaglutide, a weight-loss drug, and trevogrumab, a drug that preserves muscle mass, could significantly reduce the loss of lean mass associated with semaglutide-induced weight loss.

Results from a recent Phase 2 trial confirmed that about one-third of weight loss induced by semaglutide was due to the loss of lean mass, and that adding trevogrumab could prevent about half of this lean mass loss.

"These encouraging early data, with positive trends in lipid parameters, warrant further studies to confirm the potential of trevogrumab's role in preserving lean muscle mass during weight loss," said Julio Rosenstock, director of the Dallas Diabetes Research Center at Medical City, and a clinical professor of medicine at the University of Texas Southwestern Medical Center, Dallas.

Write to Connor Hart at connor.hart@wsj.com

(END) Dow Jones Newswires

September 17, 2025 10:15 ET (14:15 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2568097494"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2568097494\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2568097494?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-17 22:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2568097494","market":"us","top_or_hot":-1,"title":"Regeneron's Potential Obesity Treatment Could Preserve Muscle Mass","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Connor Hart \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Regeneron Pharmaceuticals said a mid-stage study of its potential obesity treatment found that it could meaningfully preserve muscle mass while enhancing fat loss. \n</p>\n<p>\n  The biotechnology company said Wednesday the combination of semaglutide, a weight-loss drug, and trevogrumab, a drug that preserves muscle mass, could significantly reduce the loss of lean mass associated with semaglutide-induced weight loss. \n</p>\n<p>\n  Results from a recent Phase 2 trial confirmed that about one-third of weight loss induced by semaglutide was due to the loss of lean mass, and that adding trevogrumab could prevent about half of this lean mass loss. \n</p>\n<p>\n  \"These encouraging early data, with positive trends in lipid parameters, warrant further studies to confirm the potential of trevogrumab's role in preserving lean muscle mass during weight loss,\" said Julio Rosenstock, director of the Dallas Diabetes Research Center at Medical City, and a clinical professor of medicine at the University of Texas Southwestern Medical Center, Dallas. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  September 17, 2025 10:15 ET (14:15 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Regeneron's Potential Obesity Treatment Could Preserve Muscle Mass</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRegeneron's Potential Obesity Treatment Could Preserve Muscle Mass\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-09-17 22:15</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Connor Hart \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Regeneron Pharmaceuticals said a mid-stage study of its potential obesity treatment found that it could meaningfully preserve muscle mass while enhancing fat loss. \n</p>\n<p>\n  The biotechnology company said Wednesday the combination of semaglutide, a weight-loss drug, and trevogrumab, a drug that preserves muscle mass, could significantly reduce the loss of lean mass associated with semaglutide-induced weight loss. \n</p>\n<p>\n  Results from a recent Phase 2 trial confirmed that about one-third of weight loss induced by semaglutide was due to the loss of lean mass, and that adding trevogrumab could prevent about half of this lean mass loss. \n</p>\n<p>\n  \"These encouraging early data, with positive trends in lipid parameters, warrant further studies to confirm the potential of trevogrumab's role in preserving lean muscle mass during weight loss,\" said Julio Rosenstock, director of the Dallas Diabetes Research Center at Medical City, and a clinical professor of medicine at the University of Texas Southwestern Medical Center, Dallas. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  September 17, 2025 10:15 ET (14:15 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0289739699.SGD","symbol_name":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2568097494","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2568097494","pubTimestamp":1758118500,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Regeneron Pharmaceuticals said a mid-stage study of its potential obesity treatment found that it could meaningfully preserve muscle mass while enhancing fat loss.The biotechnology company said Wednesday the combination of semaglutide, a weight-loss drug, and trevogrumab, a drug that preserves muscle mass, could significantly reduce the loss of lean mass associated with semaglutide-induced weight loss.Results from a recent Phase 2 trial confirmed that about one-third of weight loss induced by semaglutide was due to the loss of lean mass, and that adding trevogrumab could prevent about half of this lean mass loss.\"These encouraging early data, with positive trends in lipid parameters, warrant further studies to confirm the potential of trevogrumab's role in preserving lean muscle mass during weight loss,\" said Julio Rosenstock, director of the Dallas Diabetes Research Center at Medical City, and a clinical professor of medicine at the University of Texas Southwestern Medical Center, Dal","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU2362541513.USD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (USD) ACC","LU2023250504.SGD":"Allianz Thematica Cl AMg DIS H2-SGD","REGN":"再生元制药公司","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU1917777945.USD":"安联专题基金Cl AT Acc","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","LU2362540622.SGD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (SGDHDG) ACC","LU2106854487.HKD":"ALLIANZ THEMATICA \"AMG\" (HKD) INC","BK4585":"ETF&股票定投概念","BK4139":"生物科技","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU0882574055.USD":"富达全球健康医疗A ACC","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU1974910355.USD":"Allianz Thematica Cl AMg DIS USD","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","LU0823434583.USD":"BNP PARIBAS US GROWTH \"C\" (USD) ACC","LU0058720904.USD":"联博国际健康护理基金A","LU2237438978.USD":"Amundi Funds US Pioneer A2 (C) USD","LU0053666078.USD":"摩根大通基金-美国股票A（离岸）美元","LU0823434740.USD":"BNP PARIBAS US GROWTH \"C\" (USD) INC","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","BK4588":"碎股","LU2362541273.HKD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (HKD) ACC"},"translate_title":"再生元潜在的肥胖治疗方法可以保持肌肉质量","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"REGN":0.9},"content_text":"By Connor Hart \n\n\n \n\n\n  Regeneron Pharmaceuticals said a mid-stage study of its potential obesity treatment found that it could meaningfully preserve muscle mass while enhancing fat loss. \n\n\n  The biotechnology company said Wednesday the combination of semaglutide, a weight-loss drug, and trevogrumab, a drug that preserves muscle mass, could significantly reduce the loss of lean mass associated with semaglutide-induced weight loss. \n\n\n  Results from a recent Phase 2 trial confirmed that about one-third of weight loss induced by semaglutide was due to the loss of lean mass, and that adding trevogrumab could prevent about half of this lean mass loss. \n\n\n  \"These encouraging early data, with positive trends in lipid parameters, warrant further studies to confirm the potential of trevogrumab's role in preserving lean muscle mass during weight loss,\" said Julio Rosenstock, director of the Dallas Diabetes Research Center at Medical City, and a clinical professor of medicine at the University of Texas Southwestern Medical Center, Dallas. \n\n\n \n\n\n  Write to Connor Hart at connor.hart@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  September 17, 2025 10:15 ET (14:15 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}